Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
ACADEMIA
Academic Society Calls for Caution in Using Xofluza in Patients Under Age 12
The Japanese Association for Infectious Diseases (JAID) has issued a statement on the use of anti-influenza drugs urging doctors to use the cap-dependent endonuclease inhibitor Xofluza (baloxavir marboxil) with caution in patients under the age of 12. In clinical trials…
To read the full story
Related Article
- Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market
May 13, 2020
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- Higher Rate of Resistance to Xofluza Seen in Younger Children: Shionogi
September 3, 2019
- Resistant Virus Found in Kids Administered Xofluza: NIID
January 28, 2019
ACADEMIA
- Japan Medical Societies Release Tavneos Discontinuation Guidance
November 6, 2026
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026





